- 著者
- Takahiro Sanada Tomoko Honda Fumihiko Yasui Kenzaburo Yamaji Tsubasa Munakata Naoki Yamamoto Makoto Kurano Yusuke Matsumoto Risa Kohno Sakiko Toyama Yoshiro Kishi Takuro Horibe Yudai Kaneko Mayumi Kakegawa Kazushige Fukui Takeshi Kawamura Wang Daming Chungen Qian Fuzhen Xia Fan He Syudo Yamasaki Atsushi Nishida Takayuki Harada Masahiko Higa Yuko Tokunaga Asako Takagi Masanari Itokawa Tatsuhiko Kodama Michinori Kohara
- 出版者
- Japan Epidemiological Association
- 雑誌
- Journal of Epidemiology (ISSN:09175040)
- 巻号頁・発行日
- pp.JE20210324, (Released:2021-11-13)
- 参考文献数
- 26
- 被引用文献数
- 18
Background: Tokyo, the capital of Japan, is a densely populated city of >13 million people and thus at high risk of epidemic severe acute respiratory coronavirus 2 (SARS-CoV-2) infection. A serologic survey of anti–SARS-CoV-2 IgG would provide valuable data for assessing the city’s SARS-CoV-2 infection status. This cross-sectional study therefore estimated the anti–SARS-CoV-2 IgG seroprevalence in Tokyo.Methods: Leftover serum of 23,234 hospital visitors was tested for antibodies against SARS-CoV-2 using an iFlash 3000 chemiluminescence immunoassay analyzer (Shenzhen YHLO Biotech) with an iFlash–SARS-CoV-2 IgG kit (YHLO) and iFlash–SARS-CoV-2 IgG-S1 kit (YHLO). Serum samples with a positive result (≥10 AU/mL) in either of these assays were considered seropositive for anti–SARS-CoV-2 IgG. Participants were randomly selected from patients visiting 14 Tokyo hospitals between September 1, 2020, and March 31, 2021. No participants were diagnosed with coronavirus disease 2019 (COVID-19), and none exhibited COVID-19–related symptoms at the time of blood collection.Results: The overall anti–SARS-CoV-2 IgG seroprevalence among all participants was 1.83% (95% confidence interval [CI]: 1.66%-2.01%). The seroprevalence in March 2021, the most recent month of this study, was 2.70% (95% CI: 2.16%-3.34%). After adjusting for population age, sex, and region, the estimated seroprevalence in Tokyo was 3.40%, indicating that 470,778 individuals had a history of SARS-CoV-2 infection.Conclusions: The estimated number of individuals in Tokyo with a history of SARS-CoV-2 infection was 3.9-fold higher than the number of confirmed cases. Our study enhances understanding of the SARS-CoV-2 epidemic in Tokyo.
- 著者
- Akira Andoh Atsushi Nishida Kenichiro Takahashi Osamu Inatomi Hirotsugu Imaeda Shigeki Bamba Katsuyuki Kito Mitsushige Sugimoto Toshio Kobayashi
- 出版者
- 日本酸化ストレス学会
- 雑誌
- Journal of Clinical Biochemistry and Nutrition (ISSN:09120009)
- 巻号頁・発行日
- vol.59, no.1, pp.65-70, 2016 (Released:2016-07-01)
- 参考文献数
- 37
- 被引用文献数
- 1 163
Altered gut microbial ecology contributes to the development of metabolic diseases including obesity. In this study, we performed 16S rRNA sequence analysis of the gut microbiota profiles of obese and lean Japanese populations. The V3–V4 hypervariable regions of 16S rRNA of fecal samples from 10 obese and 10 lean volunteers were sequenced using the Illumina MiSeqTMII system. The average body mass index of the obese and lean group were 38.1 and 16.6 kg/m2, respectively (p<0.01). The Shannon diversity index was significantly higher in the lean group than in the obese group (p<0.01). The phyla Firmicutes and Fusobacteria were significantly more abundant in obese people than in lean people. The abundance of the phylum Bacteroidetes and the Bacteroidetes/Firmicutes ratio were not different between the obese and lean groups. The genera Alistipes, Anaerococcus, Corpococcus, Fusobacterium and Parvimonas increased significantly in obese people, and the genera Bacteroides, Desulfovibrio, Faecalibacterium, Lachnoanaerobaculum and Olsenella increased significantly in lean people. Bacteria species possessing anti-inflammatory properties, such as Faecalibacterium prausnitzii, increased significantly in lean people, but bacteria species possessing pro-inflammatory properties increased in obese people. Obesity-associated gut microbiota in the Japanese population was different from that in Western people.
- 著者
- Takahiro Sanada Tomoko Honda Fumihiko Yasui Kenzaburo Yamaji Tsubasa Munakata Naoki Yamamoto Makoto Kurano Yusuke Matsumoto Risa Kohno Sakiko Toyama Yoshiro Kishi Takuro Horibe Yudai Kaneko Mayumi Kakegawa Kazushige Fukui Takeshi Kawamura Wang Daming Chungen Qian Fuzhen Xia Fan He Syudo Yamasaki Atsushi Nishida Takayuki Harada Masahiko Higa Yuko Tokunaga Asako Takagi Masanari Itokawa Tatsuhiko Kodama Michinori Kohara
- 出版者
- Japan Epidemiological Association
- 雑誌
- Journal of Epidemiology (ISSN:09175040)
- 巻号頁・発行日
- vol.32, no.2, pp.105-111, 2022-02-05 (Released:2022-02-05)
- 参考文献数
- 26
- 被引用文献数
- 4 18
Background: Tokyo, the capital of Japan, is a densely populated city of >13 million people, so the population is at high risk of epidemic severe acute respiratory coronavirus 2 (SARS-CoV-2) infection. A serologic survey of anti–SARS-CoV-2 IgG would provide valuable data for assessing the city’s SARS-CoV-2 infection status. Therefore, this cross-sectional study estimated the anti–SARS-CoV-2 IgG seroprevalence in Tokyo.Methods: Leftover serum of 23,234 hospital visitors was tested for antibodies against SARS-CoV-2 using an iFlash 3000 chemiluminescence immunoassay analyzer (Shenzhen YHLO Biotech, Shenzhen, China) with an iFlash–SARS-CoV-2 IgG kit (YHLO) and iFlash–SARS-CoV-2 IgG-S1 kit (YHLO). Serum samples with a positive result (≥10 AU/mL) in either of these assays were considered seropositive for anti–SARS-CoV-2 IgG. Participants were randomly selected from patients visiting 14 Tokyo hospitals between September 1, 2020 and March 31, 2021. No participants were diagnosed with coronavirus disease 2019 (COVID-19), and none exhibited COVID-19-related symptoms at the time of blood collection.Results: The overall anti–SARS-CoV-2 IgG seroprevalence among all participants was 1.83% (95% confidence interval [CI], 1.66–2.01%). The seroprevalence in March 2021, the most recent month of this study, was 2.70% (95% CI, 2.16–3.34%). After adjusting for population age, sex, and region, the estimated seroprevalence in Tokyo was 3.40%, indicating that 470,778 individuals had a history of SARS-CoV-2 infection.Conclusions: The estimated number of individuals in Tokyo with a history of SARS-CoV-2 infection was 3.9-fold higher than the number of confirmed cases. Our study enhances understanding of the SARS-CoV-2 epidemic in Tokyo.